Lindahl acted as legal advisor to Corline Biomedical
Through the agreement, Imperative Care is given the exclusive right to use CHS™ in all types of neurovascular products given a certain level of compensation. Corline undertakes to supply CHS™-coated products according to defined specifications, but also to assist in further development and market registration of the current product. In addition, Corline will participate in the development of additional CHS™-coated products within the indication area. These products have the potential to generate revenue for Corline of approximately SEK 150 million per year and a total of more than SEK 1 billion.
Lindahl's team consisted of Hugo Norlén and Erika Svensson.
Corline's press release (in Swedish) is available here.
Do you want to know more? Contact:
Hugo Norlén
Partner | AdvokatErika Svensson
Partner | AdvokatCarousel items
-
News articles
10/10/2025
Lindahl ranked in IFLR1000 for 2025
IFLR1000 has published its rankings for 2025, where Lindahl is again recognised in several categories. The rankings cover both firms and individual lawyers and are based on extensive market analyses and client interviews.
-
Knowledge
10/10/2025
Government proposes criminal liability for unauthorised financial activity despite criticism
Despite extensive criticism, the Government is proceeding with proposals for criminal liability for unauthorised financial activity.
-
Cases and transactions
10/2/2025
Lindahl advises Copilot Capital on investment in Zendr
Lindahl has acted as legal advisor to Copilot Capital Ltd in connection with the fund’s acquisition of a majority stake in Zendr AB.
-
Portraits
8/19/2025
From demand letters to culture – Josefin on life as a summer trainee
Getting a real feel for what it's like to work as a lawyer was Josefin Mannevik's goal when she joined Lindahl's Gothenburg office as a summer trainee. A few weeks later, she has not only immersed herself in bankruptcy law, legal monitoring and si...
-
Read more news and insights?
